Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance

医学 不利影响 重症监护医学 疾病 流行病学 免疫学 免疫检查点 内科学 免疫疗法 免疫系统
作者
Filipe Martins,Sofiya Latifyan,Gerasimos P. Sykiotis,Faïza Lamine,Michel H. Maillard,Montserrat Christinet Fraga,Keyvan Shabafrouz,Camillo Ribi,Anne Cairoli,Yan Guex‐Crosier,Thierry Küntzer,Olivier Alain Michielin,Solange Peters,George Coukos,François Spertini,John A. Thompson,Michel Obéid
出处
期刊:Nature Reviews Clinical Oncology [Nature Portfolio]
卷期号:16 (9): 563-580 被引量:2301
标识
DOI:10.1038/s41571-019-0218-0
摘要

Immune-checkpoint inhibitors (ICIs), including anti-cytotoxic T lymphocyte antigen 4 (CTLA-4), anti-programmed cell death 1 (PD-1) and anti-programmed cell death 1 ligand 1 (PD-L1) antibodies, are arguably the most important development in cancer therapy over the past decade. The indications for these agents continue to expand across malignancies and disease settings, thus reshaping many of the previous standard-of-care approaches and bringing new hope to patients. One of the costs of these advances is the emergence of a new spectrum of immune-related adverse events (irAEs), which are often distinctly different from the classical chemotherapy-related toxicities. Owing to the growing use of ICIs in oncology, clinicians will increasingly be confronted with common but also rare irAEs; hence, awareness needs to be raised regarding the clinical presentation, diagnosis and management of these toxicities. In this Review, we provide an overview of the various types of irAEs that have emerged to date. We discuss the epidemiology of these events and their kinetics, risk factors, subtypes and pathophysiology, as well as new insights regarding screening and surveillance strategies. We also highlight the most important aspects of the management of irAEs. Immune-checkpoint inhibitors (ICIs) have dramatically improved the survival of patients with certain forms of cancer; however, these agents also have adverse effects that are often quite different to those of more traditional cancer therapies. In this Review, the authors describe the epidemiology, treatment and management of the various immune-related adverse events that can occur in patients receiving ICIs.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
sai完成签到,获得积分20
1秒前
秦白发布了新的文献求助10
1秒前
yh完成签到,获得积分10
1秒前
1秒前
852的应助被Minta采纳,获得10
1秒前
bkagyin的应助被lll采纳,获得10
2秒前
hhhlllmmm完成签到 ,获得积分10
3秒前
小new吗完成签到,获得积分10
3秒前
fengfengfeng完成签到,获得积分20
3秒前
zz完成签到,获得积分10
3秒前
4秒前
AstrLees完成签到 ,获得积分10
5秒前
传奇3的应助被yh采纳,获得30
5秒前
WYZ完成签到,获得积分10
6秒前
zzz发布了新的文献求助10
6秒前
刘营营完成签到,获得积分10
7秒前
7秒前
爆米花的应助被aoao采纳,获得10
7秒前
7秒前
penghuiye完成签到,获得积分10
8秒前
壮观以松完成签到,获得积分10
8秒前
9秒前
Michael完成签到,获得积分10
9秒前
10秒前
pigeon发布了新的文献求助10
11秒前
林深沉完成签到,获得积分10
12秒前
12秒前
12秒前
霜沐发布了新的文献求助10
13秒前
zhen完成签到,获得积分10
13秒前
真不爱学习完成签到 ,获得积分10
13秒前
jackhlj完成签到,获得积分10
13秒前
13秒前
开朗天问完成签到,获得积分10
13秒前
yl完成签到,获得积分10
14秒前
suisui发布了新的文献求助10
14秒前
李君完成签到 ,获得积分10
14秒前
lifeline发布了新的文献求助30
14秒前
cdercder的应助被林深沉采纳,获得10
15秒前
linhongwei发布了新的文献求助20
15秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8190478
求助须知:如何正确求助?哪些是违规求助? 9577686
关于积分的说明 21853808
捐赠科研通 7789496
什么是DOI,文献DOI怎么找? 3436407
关于科研通互助平台的介绍 2560235
邀请新用户注册赠送积分活动 2483054